WEDNESDAY, March 14 (HealthDay News) -- The Israeli remedy maker Teva Pharmaceuticals has gained the in the beginning U.S. approval to market generic Lexapro (escitalopram) to behave toward depression and general anxiety disorder, the U.S. Food and physic Administration said Wednesday.

Teva was granted 180-twenty-four hours exclusivity, so no other firm have power to market the generic medication in the United States in that timeframe, the means said in a news release.

Symptoms of major depression include depressed mood, loss of concern in once pleasurable activities, weight or relish change, sleep changes, feelings of ill-desert or worthlessness or thoughts of suicide.

Symptoms of ill-defined anxiety disorder include exaggerated worry, evermore anticipating the worst, inability to reduce and difficulty concentrating.

Escitalopram, as with similar antidepressants, has a boxed label presage about increased risk of suicidal cogitative, especially among children, teens and young adults. Other potential side effects include changes in nap pattern, low sex drive, nausea and increased sweat, the FDA said.

Generic drugs bring forth the same high quality and vigor as their brand-name predecessors, and grape-juice pass the same quality standards, the action stressed. Brand-name Lexapro, produced through Forest Laboratories, was approved by the FDA in 2002.

More denunciation

To learn more about this remedy, visit Medline Plus.

@yahoonews on Twitter, turn to a fan on Facebook